{
    "ticker": "CERS",
    "name": "Cellectar Biosciences, Inc.",
    "description": "Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for cancer. Founded in 2009 and headquartered in Madison, Wisconsin, Cellectar's mission is to improve the lives of patients afflicted with cancer through the development of its proprietary phospholipid drug conjugate (PDC) platform. This innovative technology enables the targeted delivery of therapeutic agents to cancer cells, minimizing damage to healthy tissues and improving treatment efficacy. Cellectar is advancing its lead product candidate, CLR 131, which has shown promise in treating multiple myeloma and other hematological malignancies. The company is actively engaged in clinical trials to evaluate the safety and efficacy of CLR 131 as a treatment option for patients with various types of cancer. In addition to CLR 131, Cellectar is exploring other PDC-based therapies to address unmet medical needs in oncology. With a strong commitment to scientific innovation and patient care, Cellectar Biosciences aims to become a leader in the cancer therapeutics space, providing hope and new treatment options for patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Madison, Wisconsin, USA",
    "founded": "2009",
    "website": "https://www.cellectar.com",
    "ceo": "James Caruso",
    "social_media": {
        "twitter": "https://twitter.com/Cellectar",
        "linkedin": "https://www.linkedin.com/company/cellectar-biosciences-inc-"
    },
    "investor_relations": "https://ir.cellectar.com",
    "key_executives": [
        {
            "name": "James Caruso",
            "position": "CEO"
        },
        {
            "name": "Michael A. D. T. McCarthy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "CLR 131"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cellectar Biosciences, Inc. | Innovative Cancer Treatments",
        "meta_description": "Cellectar Biosciences, Inc. is dedicated to developing novel cancer therapies using its proprietary phospholipid drug conjugate platform. Explore our innovative treatments and clinical trials.",
        "keywords": [
            "Cellectar",
            "Cancer Treatment",
            "Biotechnology",
            "Pharmaceuticals",
            "CLR 131"
        ]
    },
    "faq": [
        {
            "question": "What is Cellectar Biosciences known for?",
            "answer": "Cellectar Biosciences is known for its innovative development of cancer therapies using its phospholipid drug conjugate platform."
        },
        {
            "question": "Who is the CEO of Cellectar Biosciences?",
            "answer": "James Caruso is the CEO of Cellectar Biosciences, Inc."
        },
        {
            "question": "Where is Cellectar Biosciences headquartered?",
            "answer": "Cellectar Biosciences is headquartered in Madison, Wisconsin, USA."
        },
        {
            "question": "What is CLR 131?",
            "answer": "CLR 131 is a lead product candidate developed by Cellectar Biosciences for the treatment of multiple myeloma and other hematological malignancies."
        },
        {
            "question": "When was Cellectar Biosciences founded?",
            "answer": "Cellectar Biosciences was founded in 2009."
        }
    ],
    "competitors": [
        "CLDX",
        "KITE",
        "CRIS"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "JNJ"
    ]
}